Modulation of P-glycoprotein at the blood-brain barrier: Opportunities to improve central nervous system pharmacotherapy

Pharmacological Reviews

Volumn 60, Issue 2, 2008, Pages 196-209

  Miller, David S ^a   Bauer, Björn ^a,b   Hartz, Anika M S ^a,c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS; CYCLOSPORIN; ENDOTHELIN B RECEPTOR; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; NITRIC OXIDE SYNTHASE; OPIATE; PEPTIDE HORMONE; PREGNANE X RECEPTOR; PROTEIN KINASE C; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TUMOR NECROSIS FACTOR RECEPTOR 1; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN CAPILLARY; BRAIN CELL; CENTRAL NERVOUS SYSTEM; CROSS RESISTANCE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; LIGAND BINDING; MEMBRANE TRANSPORT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SEIZURE; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM AGENTS; ENCEPHALITIS; HIV INFECTIONS; HUMANS; IMMUNITY, NATURAL; MICROCIRCULATION; NEURODEGENERATIVE DISEASES; P-GLYCOPROTEIN; SEIZURES; SIGNAL TRANSDUCTION;

EID: 46949098349     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.107.07109     Document Type: Review

References (121)

1. Aird WC (2007a) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100:158-173.
2. Aird WC (2007b) Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 100:174-190.
3. Anderson GD and Shen DD (2007) Where is the evidence that P-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia 48:2372-2374.
4. Babakhanian K, Bendayan M, and Bendayan R (2007) Localization of P-glycoprotein at the nuclear envelope of rat brain cells. Biochem Biophys Res Commun 361:301-306.
5. Baker EK and El-Osta A (2003) The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 290:177-194.
6. Baker EK and El-Osta A (2004) MDR1, chemotherapy and chromatin remodeling. Cancer Biol Ther 3:819-824.
7. Baker EK, Johnstone RW, Zalcberg JR, and El-Osta A (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24:8061-8075.
8. Baltes S, Fedrowitz M, Tortos CL, Potschka H, and Löscher W (2007a) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 320:331-343.
9. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, and Löscher W (2007b) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52:333-346.
10. Barakat S, Demeule M, Pilorget A, Regina A, Gingras D, Baggetto LG, and Beliveau R (2007) Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J Neurochem 101:1-8.
11. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D, Mislov D, and Posavec A (2008) The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure, in press.
12. Bauer B, Hartz AM, Fricker G, and Miller DS (2004) Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413-419.
13. Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, and Miller DS (2008a) Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J Cereb Blood Flow Metab 28:1222-1234.
14. Bauer B, Hartz AM, and Miller DS (2007) Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 71:667-675.
15. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, and Potschka H (2008b) Seizure-induced up-regulation of p-glycoprotein at the blood-brain barrier through glutamate and COX-2 signaling. Mol Pharmacol 73:1444-1453.
16. Bauer B, YangX, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, and Miller DS (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70:1212-1219.
17. Begley DJ (2004) ABC transporters and the blood-brain barrier. Curr Pharm Des 10:1295-1312.
18. Bélanger MM, Gaudreau M, Roussel E, and Couet J (2004) Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3:954-959.
19. Bendayan R, Lee G, and Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
20. Bendayan R, Ronaldson PT, Gingras D, and Bendayan M (2006) In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54: 1159-1167.
21. Breedveld P, Beijnen JH, and Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24.
22. Chambers TC, McAvoy EM, Jacobs JW, and Eilon G (1990) Protein kinase C phos-phorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265:7679-7686.
23. Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, McKhann GM, Goodman RR, and Fine RL (2006) Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol 76:85-92.
24. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, et al. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285-3290.
25. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
26. Dallas S, Miller DS, and Bendayan R (2006) Multidrug resistance- associated proteins: expression and function in the central nervous system. Pharmacol Rev 58:140-161.
27. Deane R and Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4:191-197.
28. Deeken JF and Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674.
29. Droździk M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, and Sych Z (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13:259-263.
30. Dussault I and Forman BM (2002) The nuclear receptor PXR: a master regulator of "homeland" defense. Crit Rev Eukaryot Gene Expr 12:53-64.
31. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, and Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276:33309-33312.
32. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, and Kelleher D (2000) High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118:279-288.
33. Felix RA and Barrand MA (2002) P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 80:64-72.
34. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, et al. (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318.
35. Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, Sisti MB, McKhann GM, Goodman RR, Bertino JS, et al. (2006) Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 12:5770-5776.
36. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
37. Ford JM and Hait WN (1993) Pharmacologic circumvention of multidrug resistance. Cytotechnology 12:171-212.
38. Fox E and Bates SE (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447-459.
39. Francis GA, Fayard E, Picard F, and Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261-311.
40. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, et al. (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534.
41. Gao B, Stieger B, Noe B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
42. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
43. Gerstner ER and Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25:2306-2312.
44. Goralski KB, Hartmann G, Piquette-Miller M, and Renton KW (2003) Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 139:35-48.
45. Gottesman MM and Pastan I (1988) The multidrug transporter, a double-edged sword. J Biol Chem 263:12163-12166.
46. Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SE, Ulrich RG, Rushmore TH, Evers R, and Evans DC (2004) Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression. Mol Pharmacol 65:1159-1171.
47. Hartz AM, Bauer B, Fricker G, and Miller DS (2004) Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 66:387-394.
48. Hartz AM, Bauer B, Fricker G, and Miller DS (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-α and lipopolysaccharide. Mol Pharmacol 69:462-470.
49. Hawkins BT and Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173-185.
50. Hayashi K, Pu H, Andras IE, Eum SY, Yamauchi A, Hennig B, and Toborek M (2006) HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 26:1052-1065.
51. Hayashi K, Pu H, Tian J, Andras IE, Lee YW, Hennig B, and Toborek M (2005) HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem 93:1231-1241.
52. Hennessy M and Spiers JP (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55:1-15.
53. Ho EA and Piquette-Miller M (2006) Regulation of multidrug resistance by proinflammatory cytokines. Curr Cancer Drug Targets 6:295-311.
54. Holmes GL (2002) Seizure-induced neuronal injury: animal data. Neurology 59: S3-6.
55. Hong H, Lu Y, Ji ZN, and Liu GQ (2006) Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J Neurochem 98:1465-1473.
56. Huber JD, Egleton RD, and Davis TP (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24:719-725.
57. Ito S, Ohtsuki S, and Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56:246-252.
58. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, et al. (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39.
59. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
60. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, and van Tellingen O (2003) Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 9:2849-2855.
61. Kemper EM, Verheij M, Boogerd W, Beijnen JH, and van Tellingen O (2004) Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 40:1269-1274.
62. Kipp H and Arias IM (2000) Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J Biol Chem 275:15917-15925.
63. Kipp H and Arias IM (2002) Trafficking of canalicular ABC transporters in hepatocytes. Annu Rev Physiol 64:595-608.
64. Kipp H, Pichetshote N, and Arias IM (2001) Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J Biol Chem 276:7218-7224.
65. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
66. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, WarzokRW, et al. (2007) MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-β peptides - implications for the mechanisms of Aβ clearance at the blood-brain barrier. Brain Pathol 17:347-353.
67. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, and Manjunath N (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39-43.
68. Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, and Baggetto LG (2004) New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein. Nucleic Acids Res 32:3864-3876.
69. Labialle S, Gayet L, Marthinet E, Rigal D, and Baggetto LG (2002) Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64:943-948.
70. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, and Reiner PB (2001) β-Amyloid efflux mediated by P-glycoprotein. J Neurochem 76:1121-1128.
71. Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF, Schaffer JE, and Ory DS (2006) Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci USA 103:13807-13812.
72. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023.
73. Leonard GD, Fojo T, and Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411-424.
74. Löscher W (2007) Drug transporters in the epileptic brain. Epilepsia 48 (Suppl 1):8-13.
75. Löscher W and Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602.
76. Marchetti S, Mazzanti R, Beijnen JH, and Schellens JH (2007) Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927-941.
77. McRae MP, Brouwer KL, and Kashuba AD (2003) Cytokine regulation of P-glycoprotein. Drug Metab Rev 35:19-33.
78. Miller DS (2002) Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants - a case of molecular hijacking. J Biochem Mol Toxicol 16:121-127.
79. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461.
80. Molinari A, Calcabrini A, Meschini S, Stringaro A, Crateri P, Toccacieli L, Marra M, Colone M, Cianfriglia M, and Arancia G (2002) Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci 3:653-670.
81. 2-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem 87:1043-1051.
82. Ohtsuki S, Takizawa T, Takanaga H, Hori S, Hosoya K, and Terasaki T (2004) Localization of organic anion transporting polypeptide 3 (oatp3) in mouse brain parenchymal and capillary endothelial cells. J Neurochem 90:743-749.
83. Orlowski S, Martin S, and Escargueil A (2006) P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci 63:1038-1059.
84. Owen A, Chandler B, and Back DJ (2005) The implications of P-glycoprotein in HIV: friend or foe? Fundam Clin Pharmacol 19:283-296.
85. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, and Steeg PS (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13:1656-1662.
86. Pardridge WM (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3:90-105, 151.
87. Pardridge WM (2007a) Blood-brain barrier delivery. Drug Discov Today 12:54-61.
88. Pardridge WM (2007b) Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J Control Release 122:345-348.
89. Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, and Maurel P (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1-32.
90. Perloff MD, von Moltke LL, Fahey JM, and Greenblatt DJ (2007) Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 59:947-953.
91. Ronaldson PT and Bendayan R (2006) HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol 70:1087-1098.
92. Rosenfeld JM, Vargas R Jr, Xie W, and Evans RM (2003) Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-1282.
93. Sachs CW, Chambers TC, and Fine RL (1999) Differential phosphorylation of sites in the linker region of P-glycoprotein by protein kinase C isozymes α, βI, βII, γ, δ, ε, η, and ζ. Biochem Pharmacol 58:1587-1592.
94. Samoto K, Ikezaki K, Yokoyama N, and Fukui M (1994) P-glycoprotein expression in brain capillary endothelial cells after focal ischemia in rat. Acta Neurochir Suppl (Wien) 60:257-260.
95. Schlachetzki F and Pardridge WM (2003) P-glycoprotein and caveolin-1α in endothelium and astrocytes of primate brain. Neuroreport 14:2041-2046.
96. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496-7511.
97. Seelbach MJ, Brooks TA, Egleton RD, and Davis TP (2007) Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem 102:1677-1690.
98. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, and Sisodiya SM (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448.
99. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, and Brodie MJ (2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46:643-647.
100. Smith QR (2003) A review of blood-brain barrier transport techniques. Methods Mol Med 89:193-208.
101. Sorokin A (2004) Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 10:647-657.
102. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, and Hermann DM (2006) Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 9:487-488.
103. Sukhai M and Piquette-Miller M (2000) Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 3:268-280.
104. Tan EK, Chan DK, Ng PW, Woo J, Teo YY, Tang K, Wong LP, Chong SS, Tan C, Shen H, et al. (2005) Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 62:460-464.
105. Tan EK, Droździk M, Bialecka M, Honczarenko K, Klodowska-Duda G, Teo YY, Tang K, Wong LP, Chong SS, Tan C, et al. (2004a) Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett 372:240-244.
106. Tan KH, Purcell WM, Heales SJ, McLeod JD, and Hurst RD (2002) Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage. Neuroreport 13:2593-2597.
107. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, and Berkovic SF (2004b) Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63:1090-1092.
108. Teng S, Jekerle V, and Piquette-Miller M (2003) Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 31:1296-1299.
109. Terlouw SA, Masereeuw R, and Russel FG (2003) Modulatory effects of hormones, drugs, and toxic events on renal organic anion transport. Biochem Pharmacol 65:1393-1405.
110. Théron D, Barraud de Lagerie S, Tardivel S, Pelerin H, Demeuse P, Mercier C, Mabondzo A, Farinotti R, Lacour B, Roux F, et al. (2003) Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol 66:579-587.
111. Thévenod F (2003) Nephrotoxicity and the proximal tubule: insights from cadmium. Nephron Physiol 93:p87-p93.
112. Thévenod F, Friedmann JM, Katsen AD, and Hauser IA (2000) Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-ΚB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 275:1887-1896.
113. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
114. Tiwari SB and Amiji MM (2006) A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3:219-232.
115. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, and Warzok RW (2002) Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535-541.
116. -/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol Res 31:151-159.
117. Wolka AM, Huber JD, and Davis TP (2003) Pain and the blood-brain barrier: obstacles to drug delivery. Adv Drug Deliv Rev 55:987-1006.
118. Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, and Yan B (1999) Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch Biochem Biophys 368:14-22.
119. Zhang Z, Wu JY, Hait WN, and Yang JM (2004) Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66:395-403.
120. Zhu HJ and Liu GQ (2004) Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci 75:1313-1322.
121. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201.